We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.37B
AUM Growth
+$232M
Cap. Flow
-$6.42M
Cap. Flow %
-0.27%
Top 10 Hldgs %
74.03%
Holding
40
New
2
Increased
10
Reduced
8
Closed
–

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$12.4M
2
EPZM
Epizyme, Inc
EPZM
+$10.7M
3
INSM icon
Insmed
INSM
+$10.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$6.71M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.75M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$19.3M
2
GILD icon
Gilead Sciences
GILD
+$13.4M
3
UTHR icon
United Therapeutics
UTHR
+$13.4M
4
FOLD
Amicus Therapeutics
FOLD
+$6.89M
5
ABMD
Abiomed Inc
ABMD
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 94.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$326M 13.74%
1,935,300
-15,984
-0.8% -$2.42M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$274M 11.56%
3,329,581
– –
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.4B
$227M 9.56%
2,438,519
+53,800
+2% +$4.75M
UTHR icon
4
United Therapeutics
UTHR
$23.1B
$207M 8.7%
1,762,650
-104,665
-6% -$13.4M
INSM icon
5
Insmed
INSM
$28.6B
$193M 8.11%
6,171,816
+550,000
+10% +$10.5M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$152M 6.38%
1,080,342
+49,400
+5% +$6.71M
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$122M 5.13%
6,398,296
+700,000
+12% +$10.7M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$112M 4.71%
7,420,288
-520,500
-7% -$6.89M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$302M
$74.4M 3.13%
4,155,670
-47,600
-1% -$797K
PRTA icon
10
Prothena Corp
PRTA
$450M
$71M 2.99%
1,095,655
+21,700
+2% +$1.33M
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$69.2M 2.92%
2,676,393
– –
AMAG
12
DELISTED
AMAG Pharmaceuticals
AMAG
$63.5M 2.67%
3,441,233
+96,613
+3% +$1.8M
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$5.03B
$61.8M 2.6%
1,641,030
+27,700
+2% +$901K
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$49M 2.07%
787,251
-245,774
-24% -$19.3M
STAA icon
15
STAAR Surgical
STAA
$1.21B
$43.7M 1.84%
3,507,052
-22,018
-0.6% -$246K
CELG
16
DELISTED
Celgene Corp
CELG
$43.1M 1.81%
295,240
– –
IMMU
17
DELISTED
Immunomedics Inc
IMMU
$42.1M 1.77%
3,010,466
– –
ALGN icon
18
Align Technology
ALGN
$12.3B
$41.6M 1.75%
223,107
– –
KPTI icon
19
Karyopharm Therapeutics
KPTI
$48M
$38.4M 1.62%
233,239
+2,067
+0.9% +$296K
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$33.2M 1.4%
1,794,998
+7,422
+0.4% +$124K
AIMT
21
DELISTED
Aimmune Therapeutics
AIMT
$32.1M 1.35%
1,293,764
+4,045
+0.3% +$87.2K
EXAS
22
DELISTED
Exact Sciences
EXAS
$20.4M 0.86%
433,076
– –
SHPG
23
DELISTED
Shire pic
SHPG
$19.9M 0.84%
130,200
– –
GILD icon
24
Gilead Sciences
GILD
$165B
$14.3M 0.6%
175,900
-175,700
-50% -$13.4M
BIVV
25
DELISTED
Bioverativ Inc. Common Stock
BIVV
$12.1M 0.51%
+211,300
New +$12.4M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q3 2017 Portfolio in Review

As of Q3 2017, Palo Alto Investors held 40 positions worth $2.37B, up 11% from $2.14B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors's Q3 2017 filing shows 2 new, 10 increased and 8 reduced positions. Its largest new stake was Bioverativ Inc. Common Stock: 211,300 shares worth $12.1M. The largest sale was Sage Therapeutics, an estimated $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

  • Palo Alto Investors's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 211,300 shares worth $12.1M.
  • Palo Alto Investors added most to Epizyme, Inc in Q3 2017, an estimated $10.7M increase.
  • Palo Alto Investors's biggest Q3 2017 reduction was Sage Therapeutics, cutting an estimated $19.3M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $2.37B portfolio in Q3 2017.
  • Palo Alto Investors opened 2 new positions and closed 0 in Q3 2017.
  • Palo Alto Investors's portfolio value rose 11% quarter-over-quarter to $2.37B.

Based on Palo Alto Investors's 13F filing for Q3 2017, filed 14 Nov 2017.